Effect of Preoperative Stellate Ganglion Block on Postope... | NCT07271615

Studies
Effect of Preoperative Stellate Ganglion Block on Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting

NCT07271615

Sponsor

Xijing Hospital

Status

Recruiting

Last Update Posted

Dec 9, 2025Actual

Enrollment

60Estimated

Phase

Not Applicable

Conditions

Adult Patients Undergoing CABG

Interventions

Stellate Ganglion Block

Countries

China

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Dec 2025

Overall Recruitment Status or Expanded Access Status

Recruiting

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Nov 19, 2025Actual

Primary Completion Date

May 31, 2026Estimated

Completion Date

Jul 31, 2026Estimated

First Submitted Date

Nov 26, 2025

First Submission Date that Met QC Criteria

Dec 8, 2025

First Posted Date

Dec 9, 2025Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Dec 8, 2025

Last Update Posted Date

Dec 9, 2025Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

The primary objective of this study is to determine the feasibility of preoperative stellate ganglion block in reducing the incidence of postoperative atrial fibrillation in patients undergoing CABG.

Detailed Description

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not Applicable

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

60Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Control group（C group）	No Intervention	the best available treatment without block (usual care)
Stellate Ganglion Block（S group）	Other	Ultrasound-guided stellate ganglion block with ropivacaine	Procedure: Stellate Ganglion Block

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Stellate Ganglion Block	Procedure	Ultrasound-guided stellate ganglion block with ropivacaine	Stellate Ganglion Block（S group）

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
postoperative atrial fibrillation（POAF）		within 7 days postoperatively

Secondary Outcomes

Measure	Description	Time Frame
cumulative time spent in postoperative atrial fibrillation		within 7 days postoperatively
the need for antiarrhythmic medications to treat postoperative atrial fibrillation		within 7 days postoperatively

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

more than 18 years old
undergoing CABG
Provide informed consent

Exclusion Criteria:

History of prior cardiac surgery or atrial fibrillation ablation;
Emergency coronary artery bypass grafting (CABG);
Concomitant cardiac procedures (e.g., congenital heart disease repair, left ventricular reconstruction, valve surgery, or aortic surgery);
Critical preoperative status requiring mechanical or pharmacological support before CABG;
Left ventricular ejection fraction (LVEF) <35%;
History of atrial fibrillation (defined as a supraventricular tachyarrhythmia characterized by rapid and irregular atrial electrical activity);
Significant mitral valve disease (mitral valve area <1.5 cm² or regurgitant jet area <4 cm²), significant aortic valve disease (valve area <1.5 cm² or regurgitant jet-to-left ventricular outflow tract ratio >25%);
Severe left atrial enlargement (left atrial anteroposterior diameter >55 mm);
Poorly controlled hyperthyroidism;
Conditions requiring radiotherapy, chemotherapy, or long-term hormonal therapy;
Patients with known clinical contraindications to stellate ganglion block (SGB).

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided